Clinical trial
A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease.
NCT00236574 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease.
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2001
- Completion date
- November 30, 2003
- Enrollment
- 974 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.